10-Q quarterly report · filed Nov 12, 2026

Absci Corp (ABSI) Q3 2026 10-Q Quarterly Report

Short answer

Absci Corp (ABSI) filed its Q3 2026 10-Q quarterly report on Nov 12, 2026 for the quarter ended Sep 30, 2026. Quarterly revenue was $304,000 (down 19.6% year over year) with net income of −$33M.

Q3 2026 key financials · XBRL

Revenue
$304,000
−19.6% YoY · −4.4% QoQ
Net income
−$33M
−16.0% YoY · −0.3% QoQ
Operating margin
-11511.2%
EPS (diluted)
−$0.20
+0.0% YoY · +4.8% QoQ

Source: XBRL data from the Absci Corp (ABSI) Q3 2026 10-Q on SEC EDGAR. USD.

Absci Corp Q3 2026 10-Q analysis

AI summary of MD&A and risk factor updates

Management Discussion & Analysis

  • Revenue $0.3M, down 20% YoY from $0.4M, reflecting milestone timing and program mix
  • Operating loss $35.0M vs $30.2M YoY, with R&D expense $23.6M, up 22%
  • Lead program ABS-201: positive interim safety data, half-life at least 65 days
  • Cash, equivalents and marketable securities $173.7M; operating cash used $83.3M through nine months
  • June offering generated $93.6M; management expects liquidity sufficient for at least 12 months

Risk Factors

  • Newly added BIOSECURE Act risk: WuXi AppTec’s June 2026 designation was preliminarily enjoined in August 2026
  • Regulatory risk: CMS finalized GLOBE Model for 2027, potentially reducing partner revenue, milestones and royalties
  • Clinical risk: ABS-201 Phase 1/2a trial continues dosing MAD cohorts in Australia
  • Financial risk: $173.7 million cash, equivalents and marketable securities expected to fund at least 12 months
  • Operating risk: No partner has licensed related intellectual property for clinical or commercial use as of November 12, 2026

Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K

Other Absci Corp quarterly reports

Ask about this quarter

Compare quarters, check guidance or see what insiders and funds did around the report.